A Study to Evaluate ATP150/ATP152, VSV-GP154 and Ezabenlimab in Patients With KRAS G12D/G12V Mutated PDAC (KISIMA-02)
Status:
Recruiting
Trial end date:
2027-03-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to test an experimental treatment (immunotherapy) in
pancreatic cancer patients. The main research objectives are:
- to evaluate if the KISIMA-02 treatment is safe and well-tolerated (first part)
- to evaluate if the KISIMA-02 treatment has an impact on the time to observe a possible
reappearance of the tumor (second part)
Participants will receive:
i) a therapeutic protein vaccine ATP150 or ATP 152 ii) a viral vector VSV-GP154 iii) an
immune checkpoint inhibitor Ezabenlimab In the second part of the study, researchers will
compare treatment group versus observational group.